- Recruiting
NCT03871829: Phase 2: Retreatment in Participants With Myeloma Who Have Been Previously Rx with Dara
Updated: May 26, 2022
54767414MMY2065
NCT03871829: Phase 2: Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
DKd
Kd

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Sponsor
Janssen Research & Development, LLC
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT03871829
Official Title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab Retreatment
First Posted : March 12, 2019
Click here to see details on ClinicalTrials.gov
Drug: Carfilzomib 20 mg/m^2
Drug: Carfilzomib 70 mg/m^2
Drug: Dexamethasone 40 mg
Drug: Dara-SC 1800 mg
Drug: Dexamethasone 20 mg
Locations
United States, Arizona
United States, California
United States, Indiana
United States, Michigan
United States, Minnesota
United States, Missouri
United States, New York
United States, Ohio
United States, Texas
United States, Wisconsin
Canada, Alberta
Europe
France
Germany
Italy
Netherlands
Spain
Belgium
Denmark
Greece
Poland
Brazil
Asia
Russian Federation